OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Análisis de IA de OKYO PHARMA LTD
Haz clic en cualquier análisis a continuación para obtener información instantánea de la IA de finAgent
Últimos análisis de IA sobre OKYO PHARMA LTD
Aún no hay hilos de IA disponibles para esta empresa.